PROTAC

ERD-308, a PROTAC Degrader of ER, Has Potential to Treat ER+ Breast Cancer Treatment

April 28, 2025

In previous blogs, I have introduced some compounds based on PROTAC technology, including SJFδ, MS4077, BSJ-03-123, A1874, HJB97, Olutasidenib. Today, I’d like to introduce another novel compound ERD-308 as a highly potent PROTAC degrader…

📌
0💬 read more

MS4077 is an Anaplastic Lymphoma Kinase PROTAC (Degrader)

April 27, 2025

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, which belongs to the insulin receptor kinase subfamily. ALK correlates with oncogenesis in different types of cancers, such as anaplastic large-cell non-Hodgkin’s lymphoma…

📌
0💬 read more